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Abstract
Introduction: Idiopathic Pulmonary Fibrosis (IPF) is the most common disease in the subgroup
of idiopathic interstitial pneumonias. It is inevitably associated to a bad prognosis, although
assuming a highly variable clinical course.
Methods: Patients with IPF, observed at Interstitial Lung Diseases outpatient clinic of Centro
Hospitalar de São João -- Porto, Portugal, were identified and clinical, functional, radiological
and bronchoalveolar lavage (BAL) parameters were reviewed. Their clinical course and survival
were analyzed in order to identify prognostic factors.
Results: Eighty-one patients were included, with a mean age at diagnosis of 63.8 years old. At
diagnosis, the main functional abnormalities were restrictive physiology, reduced lung diffusion
and exercise capacity impairment. Clinical course was mainly slowly progressive (72.3%). Ten
patients (13.2%) had a rapid progression and 11 (14.5%) patients had an acute exacerbation
during the course of the disease. IPF’s rapid progression was associated to a higher functional
impairment at diagnosis, namely in what is related with Functional Vital Capacity (FVC) and Total
Lung Capacity (TLC). Median survival was 36 months. A significant difference in survival was
observed among different types of clinical course -- 41 months for slow progressors and 9 months
for rapid progressors. Lower levels of FVC, TLC, six-minute walk test (6MWT) distance and
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rest PaO2, and higher BAL neutrophil count were associated with poorer survival in univariate
analysis.
Conclusion: The analysis of this group of IPF patients confirms two clearly different pheno-
types, slow and rapid progressors. Those phenotypes seem to have different presentations and
a remarkably different natural history. These results could mean different physiopathologic
pathways, which could implicate different therapeutic approaches.
© 2011 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L. All rights
reserved.
PALAVRAS-CHAVE
Fibrose Pulmonar
Idiopática;
Sobrevivência;
Prognóstico
Fibrose Pulmonar Idiopática -- Apresentac¸ão clínica, evoluc¸ão e factores prognósticos
basais numa coorte portuguesa
Resumo
Introduc¸ão: A Fibrose Pulmonar Idiopática (FPI) é a patologia mais comum no subgrupo das
Pneumonias Intersticiais Idiopáticas. Apesar de uma grande variabilidade no tipo de evoluc¸ão
clínica, está inexoravelmente associada a um mau prognóstico.
Material e métodos: Foram identificados doentes com FPI, observados na consulta de Doenc¸as
Pulmonares Difusas do Centro Hospitalar de São João, Porto, e revistos os seus parâmetros
clínicos, funcionais, radiológicos e do lavado broncoalveolar (LBA). A evoluc¸ão clínica e sobre-
vivência foram avaliadas, tendo sido igualmente identificados factores prognósticos.
Resultados: Foram incluídos 81 doentes com uma média de idade de 63.8 anos. Na altura
do diagnóstico, as principais alterac¸ões funcionais identificadas foram restric¸ão, reduc¸ão da
difusão pulmonar e da capacidade de exercício. A maioria dos doentes (72.3%) apresentou
uma evoluc¸ão clínica lentamente progressiva. Em 10 doentes (13.2%), foi observada uma
evoluc¸ão rapidamente progressiva e 11 (14.5%) apresentaram exacerbac¸ão aguda. Verificou-
se uma associac¸ão entre a evoluc¸ão rapidamente progressiva e uma maior gravidade funcional
ao diagnóstico, nomeadamente na Capacidade Vital Forc¸ada (CVF) e Capacidade Pulmonar Total
(CPT). A sobrevivência mediana foi de 36 meses. Verificou-se uma diferenc¸a estatisticamente
significativa na sobrevivência entre os diferentes grupos de evoluc¸ão clínica - 41 meses para os
doentes com evoluc¸ão lentamente progressiva e 9 meses para os doentes com evoluc¸ão rapida-
mente progressiva. Valores inferiores de CVF, CPT, distância na Prova da marcha dos 6 minutos
e PaO2 em repouso, bem como o maior grau de neutrofilia no LBA estiveram associados a uma
sobrevivência inferior em análise univariada.
Conclusão: A análise deste grupo de doentes com FPI confirma a existência de 2 fenótipos clara-
mente distintos, o de evoluc¸ão lenta e o de evoluc¸ão rapidamente progressiva. Estes fenótipos
têm uma diferente apresentac¸ão clínica e uma história natural da doenc¸a claramente distinta,
sugerindo a presenc¸a de diferentes mecanismos fisiopatológicos, os quais poderão implicar
diferentes abordagens terapêuticas.
© 2011 Sociedade Portuguesa de Pneumologia. Publicado por Elsevier España, S.L. Todos os
direitos reservados.
Introduction
Idiopathic Pulmonary Fibrosis (IPF) is the most common dis-
ease in the subgroup of Idiopathic Interstitial Pneumonias.1,2
It is a disease of the elderly, with presentation occurring usu-
ally in the sixth and seventh decades, more frequently in
men.3--5 Both etiology and key mechanisms of pathogenesis
remain to be understood.3
IPF’s typical histological pattern is Usual Interstitial
Pneumonia (UIP).6 However, in the absence of biopsy, IPF
can be diagnosed based on ATS/ERS criteria -- a group of
clinical, radiological and physiological parameters, inter-
nationally accepted and validated, in which typical signs
at Chest High-Resolution Computerized Tomography (HRCT)
have a prominent role.3,7
The clinical history of the disease is quite variable;
there is usually a slow physiological deterioration, but in
some patients there is a faster decline in lung function and
death occurs within 6--12 months after diagnosis.8--10 Oth-
ers experience an acute exacerbation during the course of
the disease with a sudden worsening of respiratory symp-
toms, hypoxemia and the appearance of new radiological
infiltrates without an identifiable cause.11,12
Despite different types of clinical course, IPF is inevitably
associated with a poor prognosis, with a median survival
of 2--3 years.8,13 No proven effective pharmacological ther-
apy has yet been found.3 Some prognostic factors have
already been described, which may have implications for
potential therapy, particularly when to refer for lung trans-
plant, which up until now has been the only therapy with
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demonstrated survival benefit.14,15 Recently, Pirfenidone,
an oral antifibrotic and anti-inflammatory drug, has been
approved by EMEA (European Medicines Agency) for the
treatment of IPF.
Our aim was to describe the clinical presentation and the
course of IPF patients who have been evaluated in recent
years in our Interstitial Lung Diseases (ILD) outpatient clinic
and analyze factors associated with survival and the clinical
course.
Methods
Patients diagnosed with IPF, who attended an ILD outpatient
clinic in Hospital de São João, a tertiary reference center
in Oporto, Portugal, were identified. IPF diagnosis was
obtained through an UIP compatible histology by surgical
lung biopsy in 25 patients (30.9%). In 56 patients (69.1%),
IPF diagnosis was based on ATS/ERS criteria (according
to 2002 consensus).2 Whenever atypical signs were found
on HRCT or other atypical characteristics that could raise
diagnostic issues, patients were sent for surgical lung
biopsy. Patients whose UIP pattern could be explained by
other diseases (connective tissue diseases, hypersensitivity
pneumonitis, drug lung toxicity and other ILDs whose final
stage is fibrosis), were excluded.
Medical records were retrospectively analyzed. Patients
were characterized clinically, physiologically and by radio-
logical findings, at the time of diagnosis.
Rest and exercise physiological assessments (spirome-
try, lung diffusing capacity for carbon monoxide -- DLCO,
Total Lung Capacity -- TLC, six-minute walk test -- 6MWT
and cardiopulmonary exercise test) were measured accord-
ing to ERS and ATS recommendations16--20 and results were
expressed as percentages of the normal predicted val-
ues. Physiological parameters obtained after any medication
that could probably modify the course of the disease were
excluded.
Some patients were not able to perform the exercise
capacity evaluation due to a high degree of disability at
diagnosis.
All patients performed HRCT scan at diagnosis. As this was
a retrospective study, some of the HRCT images were not
available for analysis, although all the reports were accessi-
ble. For imaging characterization, chest HRCT images were
analyzed by two radiologists and the extent of the disease
was calculated as a fibrotic score,21 the same used to vali-
date the Composite Physiologic Index (CPI).
Bronchoalveolar lavage (BAL) was performed on an out-
patient basis. At the time of BAL, no symptoms or signs
suggestive of respiratory infection or exacerbation of the
disease were observed. The performance and processing
of BAL was carried out according to guidelines of the
ERS Task Group on BAL.22 Total and differential cell count
was classified according to the values proposed by ERS
Task Group on BAL (lymphocytosis > 15%, neutrophilia > 3%,
eosinophilia > 0.5%).22
Open lung biopsy was performed under general anes-
thesia and the most common approach used was a limited
anterolateral thoracotomy via a 4± 10 cm submammary inci-
sion, which allowed access to segments of different lobes in
order to obtain multiple biopsy specimens. Open lung biopsy
was always performed through thoracotomy. The site of the
biopsy was decided on the basis of the HRCT scan. Biopsy
samples were observed and evaluated independently by two
pathologists.
To evaluate the occurrence of pulmonary hypertension,
all patients performed echocardiography. Only the patients
referred for lung transplantation underwent right heart
catheterization.
Clinical course was classified as slow progression, rapid
progression and acute exacerbation (AE-IPF). Rapid progres-
sion was differentiated from slow progression by a shorter
duration of symptoms at diagnosis (<6 months) and a more
rapid clinical deterioration.10 AE-IPF was defined as a sud-
den worsening of respiratory symptoms with hypoxemia and
appearance of new radiological infiltrates without an iden-
tifiable cause.11
Patients included had IPF diagnoses established between
2000 and 2010. They were followed during the course of the
disease, until death or lung transplant.
Statistical analysis
Kolmogorov--Smirnov test was used to check for normality
of the distributions in all continuous variables. Medians for
covariates and percentages of factors were computed and
baseline differences in patients with slow versus rapid pro-
gression were assessed through U Mann--Whitney, Chi square
or Fischer exact test, as appropriate.
Median survival was estimated using Kaplan--Meier sur-
vival curves. Patients were censored at the time of death
or lung transplant. Follow-up was stopped after 48 months,
to increase statistical power of the study. To identify the
strength of prognostic factors, Hazard Ratios (and their
respective 95% confidence intervals) were computed using
univariate Cox regression models.
All analyses were performed using SPSS® software v. 18.
A p-value < 0.05 was considered significant.
Results
Patients’ characterization at diagnosis
Eighty-one patients were included, 56 (69.1%) men and 25
(30.9%) women. Mean age at diagnosis was 63.8± 10.2 years
old. Two patients (2.5%) had familial IPF. A smoking history
was found in 51.9% (27.5% current and 72.5% former smok-
ers) accounting for a mean of 37.5 pack-years. The main
symptom at presentation was dyspnea (96.3%), followed by
cough (77.9%). Median time between beginning of symptoms
and time of diagnosis was 12 months.
Restrictive physiology and reduced lung diffusion capac-
ity were the main functional abnormalities (Table 1) as well
as exercise capacity impairment. 6MWT was taken into con-
sideration for 40 patients, with amean (Standard deviation --
SD) distance of 369.6 (149.4) meters and a mean (SD) lowest
oxygen saturation of 81.5 (8.1) %. Cardiopulmonary Exercise
Test was looked at for only 15 patients with a mean (SD)
peak oxygen consumption of 66.6 (18.4)%.
HRCT scan fibrotic score was measured in 42 patients.
Mean (SD) fibrotic score was 10.8 (2.3).
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Table 1 Physiological assessment in IPF patients at time of
diagnosis.
Physiological assessment at diagnosis Mean SD
FVC (n = 71) 74.8 ±20.2
FEV1 (n = 71) 80.8 ±19.3
FEV1/FVC (n = 69) 85.6 ±7.8
TLC (n = 65) 70.8 ±15.7
DLCO (n = 57) 45.8 ±16.4
PaO2 (n = 62) 71.3 ±14.5
PaCO2 (n = 56) 40.1 ±4.8
The prevalence of emphysema in this IPF cohort was
26.4% (14/53 HRCT available for reevaluation). Patients with
emphysema were younger -- 61.8 vs. 69.9 years (p = 0.042),
had a higher smoking load -- 28.3 vs. 10.7 pack-years
(p = 0.035), lower FEV1/FVC -- 79 vs. 86.9% (p = 0.001) and
more severely compromised diffusion capacity (DLCO) -- 36.8
vs. 49.9% (p = 0.016).
BAL was performed in 56 patients at the time of diagno-
sis, with neutrophilia (mean = 10.8, SD = 2.3) in 52 (92.9%)
patients, eosinophilia (mean = 5.1, SD = 5.0) in 48 (85.7%)
patients and mild lymphocytosis being detected in 14 (25%)
patients (mean = 12, SD = 7.8).
Clinical course
Regarding therapeutic approach, ATS/ERS statement was
followed and, if there were no contraindications, low doses
of corticosteroids (86.4%) and immunosuppressive drugs
(65.4%), preferably azatioprine or alternatively, cyclophos-
phamide were used. After the publication of IFIGENIA trial23
in 2005, N-acetylcysteine (1800mg/day) was added to this
regimen (51.9%). Up until now, Pirfenidone has not been
available in Portugal. Moreover, when the included IPF
patients were diagnosed, Pirfenidone was still not approved
by EMEA and there was no Portuguese center participating
in any clinical trial using this drug.
Since a protocol was established in 2007 with Hospital
Juan Canalejo (Corun˜a) and Hospital Santa Marta (Lisbon),
patients under 65 years have been considered to lung trans-
plantation. As this series includes patients diagnosed since
2000, there is still only a small percentage of transplanted
patients. To be precise, 9 patients (7.4%) were selected
for lung transplantation and single lung transplant was per-
formed in 6 (2 patients were excluded because of infection
by Aspergillus fumigatus). Another patient is on waiting
list.
Clinical course (n = 76) was mainly slowly progressive
(72.3%). In 10 patients (13.2%), IPF had a rapid progression
and 11 (14.5%) patients had an AE-IPF during the course of
their disease.
IPF’s rapid progression (Table 2) was found to be associ-
ated to a higher functional impairment at diagnosis, namely
Table 2 Baseline factors and its association with clinical course (rapid versus slow progression).
N (%) or mean± SD
Slow progressors (n = 55) Rapid progressors (n = 10) p
Age 69.2± 9.8 69.4± 11.2 0.954
Sex
♂ 37 (67.3%) 8 (80%) 0.346
♀ 18 (32.7%) 2 (20%)
Smoke history
No 21 (40.4%) 8 (88.9%) 0.020
Yes 31 (59.6%) 1 (11.1%)
FVC 76.2± 21.0 57.5± 10.9 0.003
TLC 72.2± 16.1 59.8± 10.7 0.032
DLCO 44.6± 14.7 38.1± 12.5 0.204
PaO2 73.6± 16.6 63.3± 11.4 0.055
6MWT distance (m) 377.2± 131.2 265.2± 226.4 0.318
6MWT Min SatO2 81.7± 7.9 77.3± 8.6 0.242
Fibrotic score 11.2± 2.3 11.0± 2.2 0.192
Pulmonary hypertension
No 36 (87.8%) 5 (62.5%) 0.110
Yes 5 (12.2%) 3 (37.5%)
% Lymph 11.5± 7.5 12.9± 5.2 0.241
% Neutroph 10.5± 9.8 12.6± 8.2 0.272
% Eosinoph 5.9± 5.3 4.2± 5.3 0.154
% Lymph -- percentage of lymphocytes at BAL differential count; % Neutroph -- percentage of neutrophils at BAL differential count; %
Eosinoph -- percentage of eosinophils at BAL differential count. Significant results are presented in bold.
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with FVC (p = 0.003) and TLC (p = 0.032). A smoking his-
tory was associated with a slowly progressive clinical course
(p = 0.020).
Most IPF patients (69.6%) died of causes directly related
to the disease -- respiratory failure, while in 13 patients
(23.2%), the cause of death was due to other causes. Four
patients (7.1%) died of post-lung transplant complications.
AE-IPF occurred in 11 patients. Among them, 6 (54.5%)
died during the episode and 2 were submitted to lung trans-
plantation, dying due to post-transplant complications.
Survival
Median survival was 36 months (Fig. 1). Twenty-five patients
were still alive at the time of evaluation.
Factors found to be associated with poorer survival,
in univariate analysis (Table 3), were lower levels of FVC
(p = 0.000), TLC (p = 0.001), 6MWT distance (p = 0.014) and
rest PaO2 (p = 0.008), as well as higher BAL neutrophil count
(p = 0.039).
It was not possible to identify cut-points for each pro-
gnostic factor because of the lack of statistical power (small
sample size).
Table 3 Survival Prognostic Factors of IPF patients.
HR (CI 95%) unadjusted p
Age 1.01 (0.98--1.04) 0.505
Sex
Men Ref
Women 0.78 (0.40--1.51) 0.451
Smoke history
No Ref
Yes 0.60 (0.33--1.09) 0.092
FVC 0.96 (0.94--0.98) 0.000
TLC 0.96 (0.94--0.98) 0.001
DLCO 0.98 (0.96--1.01) 0.187
DLCO< 40 1.97 (0.96--4.01) 0.063
DLCO≥ 40 Ref
PaO2 0.97 (0.94--0.99) 0.008
6MWT
Meters 1.00 (0.99--1.00) 0.014
6MWT
Lowest SatO2 1.00 (0.95--1.05) 0.894
SatO2≤ 88 1.63 (0.38--6.98) 0.512
SatO2 > 88 Ref
VO2 0.97 (0.91--1.03) 0.244
HRCT fibrotic score 1.08 (0.90--1.29) 0.407
Pulmonary hypertension
No Ref
Yes 1.10 (0.39--3.15) 0.854
Lymph % 1.00 (0.95--1.05) 0.999
Neutroph % 1.03 (1.00--1.06) 0.039
Eosinoph % 0.97 (0.90--1.05) 0.398
HR -- Hazard ratio.
Testing cut-points of the baseline prognostic factors
described in the last consensus document3 (DLCO< 40% of
predicted; desaturation≤ 88% during 6MWT; presence of
pulmonary hypertension), had no significant associations in
this sample, although estimates follow the expected direc-
tion.
No significant difference in survival rates was found
between IPF patients with and without emphysema.
Median survival was 41 months in slow progressors and 9
months in rapid progressors (Fig. 1).
Among slow progressors, lower levels of FVC (p = 0.001),
TLC (p = 0.012) and 6MWT distance (p = 0.026) were associ-
ated to a reduced survival.
No prognostic factors were found in rapid progres-
sors (reduced statistical power due to a small number of
patients).
Discussion
The evaluation of this cohort of IPF patients from the
north of Portugal showed the usual features that character-
ize this disease, in terms of clinical, functional, radiologic
parameters and outcome. Although some baseline progno-
stic factors were associated with overall survival in this
series, the main issue is related with the sort of clinical
course, more exactly the distinction between slow progres-
sion and rapid progression since their outcome and survival
are significantly different.
Mean age at diagnosis was consistent with literature,3,24
as well as the higher prevalence of males. Familial IPF
may be undervalued. In fact, some patients report fam-
ily deaths from unspecified respiratory diseases. Cigarette
smoking is strongly associated with IPF, namely in those
patients with heavy smoking history, more precisely more
than 20 pack years.25,26 In this study, the proportion of smok-
ers and former smokers was lower than expected, as was the
case in other series.27,28 However, in the 15 patients aged
under 60 years old, 80% had a history of cigarette smok-
ing, so we can speculate that excluding ageing, smoking
history could have been a significant risk factor for IPF in
this sample. Twelve months was the median time between
beginning of symptoms and diagnosis. Kim et al.1 reported a
period of 6 months to 2 years of symptoms preceding diag-
nosis. In fact, not only patients tend to attribute the initial
breathlessness to ageing, but also primary care physicians
tend to focus the clinical investigation on cardiac diseases
and other respiratory diseases such as COPD, based on their
higher prevalence. However, in this cohort of patients there
was an increasing number of patients referred by general
practice over the last few years, which could be related to
the widespread use of CT scans.
Recently, a new syndrome has been described -- Com-
bined Pulmonary Fibrosis and Emphysema (CPFE), resulting
from the association of IPF and emphysema.29,30 The per-
centage of CPFE found in this cohort is in line with other
publications.30 In this study, some previously described
distinctive features were observed, namely a stronger asso-
ciation with smoking, lower levels of FEV1/FVC and a higher
compromise on diffusion capacity (DLCO). However, some
authors describe a negative impact on prognosis when IPF
is associated with emphysema.30 This negative impact is
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Figure 1 Kaplan--Meier survival curves for all IPF patients (left) and for slow and rapid progressors (right) -- months.
strongly associated to pulmonary hypertension.30 In this
study we did not find a significant difference in survival or
in the occurrence of pulmonary hypertension.
Lymphocytosis was detected in 14 patients (25%). They
presented a mild lymphocytosis (mean of 22.8%) and no
exposure to suspected agents was detected. Also, in 50% of
these patients a lung biopsy was performed to rule out other
differential diagnoses. Moreover no difference on survival
was found between patients with or without BAL lymphocy-
tosis.
Clinical course cannot yet be predicted accurately. In
this sample, 13.2% of patients experienced an accelerated
decline, already described in literature.10 However, criteria
for classification of IPF progression are not well established.
The definition of rapid progressors is based on a time-period
between symptoms and diagnosis of less than 6 months,
associated with an accelerated decline.1,10 The difference in
survival between low and rapid IPF progressors is remarkable
(41 and 9 months, respectively). Although this subject is still
not clearly understood, these groups must represent differ-
ent phenotypes in IPF. At a univariate analysis, lower levels
of FVC and TLC were associated to a rapidly progressive
disease. Non-smokers were also associated to rapid progres-
sion. This was already described in other studies, also with
a better survival in current smokers;31 and there is no clear
explanation for this. Some data suggest that cigarette smoke
inhibits lung fibroblast proliferation as well as chemotaxis,
and may that way impair lung repair after lung injury.32 A
recent study contradicts this fact, showing a better outcome
for non-smokers, and assuming that the better outcome pre-
viously reported for smokers was compatible with a healthy
smoker lead-time effect (reflecting a less severe disease at
presentation).33
AE-IPF has been a main focus of interest. The results
of this study are in line with publications on this subject,
both in terms of incidence and mortality. In fact, inci-
dence of AE-IPF is 10--15% of all IPF patients, according
to two large randomized clinical trials 34,35 and its mortal-
ity is high, ranging between 50 and 100%.12,36--38 Excluding
patients who received lung transplant, this study registered
an in-hospital mortality of 66.7% in AE-IPF. There have been
several attempts to identify acute exacerbations predictors,
without success.38 In fact, the occurrence of AE-IPF does not
appear to be related to the severity of pulmonary function
impairment.38 It was the same for this study, no factor was
identified which could predict its occurrence.
Median survival in this sample is in line with other
studies.39,40 Predictors of mortality in IPF have been divided
in baseline and dynamic predictors.41 In fact, prognosis in IPF
should involve the integration of baseline and longitudinal
data. This study only meant to evaluate baseline predictors.
Factors associated with a poorer survival in this cohort at
univariate analysis are related to higher functional decline
(FVC, TLC), worse oxygenation (PaO2), reduced tolerance to
exercise (distance in 6MWT) and higher neutrophil count on
BAL.
When reviewing the literature, what is remarkable is
the great variability in prognostic factors. There are sev-
eral reasons for this, such as series with a small number
of patients or the inclusion of patients with co-morbidities
which act as confounding factors. Most studies have differ-
ent diagnostic and therapeutic approaches relating to the
patients included; although when we consider the lack of
effective pharmacologic therapeutics, this latter factor is
hardly likely to affect the accuracy of the results. More-
over this cohort of patients was divided according to their
phenotypes, since the prognostic factors must be adapted
to each of the three types of outcome as their outstanding
different clinical course. The prognostic factors concerned,
that is lower levels of FVC, TLC and 6MWT distance, are all
significantly associated with the low progression subgroup.
The lack of any association with rapid progressors may be
explained by the fact that the sample size was too small to
give a significant result.
Several studies have tended to ascribe prognostic values
to baseline pulmonary function tests, giving the impression
that a higher functional decline is significantly associated
with a reduced survival. The factors concerned are usually
FVC27,42--44 and TLC,42,44 with higher evidence supporting the
first parameter. The association of DLCO with reduced sur-
vival rates is a consistent finding across the literature.42--45
It is a fact that lower diffusion capacity reflects a greater
extent of fibrosis and increased severity of the disease.
However, in this sample there was no prognostic impact.
There are some studies which show baseline PaO2 at rest
as a predictor of mortality,8,27,43,46 although there are also
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some contradictory results.44,47 Higher degrees of hypox-
emia occur in more advanced stages of the disease but
whether this can be considered as a prognostic factor or
not, is yet to be established. There are studies which
have ascribed prognostic significance in relation to survival
rates to 6MWT parameters,48--51 either linked to the walk-
ing distance or to desaturation peak, but these results are
underestimated due to lack of standardization and repro-
ductability of this test.
BAL neutrophilia has been associated with severity as in
other diffuse lung disease such as sarcoidosis.52 There is also
some evidence that a higher level of neutrophilia may be
associated with lower survival rates.53 Although neutrophilia
is usually described as a baseline prognostic factor in uni-
variate analysis, multivariate analysis does not confirm this
association according to studies published in peer-review
literature.54,55
Pulmonary hypertension should have a multifactorial
pathogenesis for IPF. Several studies point out pulmonary
hypertension to be a predictor of mortality,56,57 but usually in
longitudinal studies. In our sample, pulmonary hypertension
at baseline did not act as a prognostic factor.
Some coefficients21,58 have been proposed in order to
combine different parameters. For instance, the Compo-
site Physiologic Index, which includes FVC, FEV1, DLCO
and fibrosis extension on HRCT scan, has been success-
fully tested at baseline and longitudinal studies.21,59 This
could be a way to predict outcome more accurately and
to provide a more precise timing of the progression of the
disease.
In conclusion, IPF is inevitably associated with a poor
prognosis. However, different phenotypes seem to be emerg-
ing, based on the striking differences in clinical course. A
more accurate prediction of the outcome at the moment of
diagnosis would improve patient management, particularly
in the time to reference to lung transplant, which is the only
therapy with demonstrated survival benefit.
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